TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32895266

Group type: EXPERIMENTAL
Intervention: WHO four-symptom TB screening tool
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Testing for TB
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: TB test results
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Initiation of TB treatment
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: CD4 count
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: ART initiation
Number of subjects: 834
Study: 32895321

Group type: EXPERIMENTAL
Intervention: Coiling or balloon-assisted coiling
Number of subjects: 335
Study: 32895922

Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 65
Study: 32896200

Group type: EXPERIMENTAL
Intervention: Avatar-Facilitated Life Review Intervention
Number of subjects: 0
Study: 32896211

Group type: EXPERIMENTAL
Intervention: Electronic cigarette (EC) vapers
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Tobacco cigarette (TC) smokers
Number of subjects: 33

Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 33
Study: 32896301

Group type: EXPERIMENTAL
Intervention: Venetoclax with 10-day decitabine
Number of subjects: 168
Study: 32896640

Group type: EXPERIMENTAL
Intervention: Skin tape sampling technique (STS)
Number of subjects: 63
Study: 32896756

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Explanatory models in psychotherapy
Number of subjects: 20
Study: 32896803

Group type: EXPERIMENTAL
Intervention: IL-6 levels
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Cytokines and blood parameters
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Bilirubin levels
Number of subjects: 403
Study: 32896832

Group type: EXPERIMENTAL
Intervention: Telephone calls
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Video calls
Number of subjects: 132
Study: 32896928

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 6784
Study: 32897169

Group type: EXPERIMENTAL
Intervention: MRI-guided transurethral ultrasound ablation (pTULSA)
Number of subjects: 10
Study: 32897236

Group type: EXPERIMENTAL
Intervention: Biannual topical application of silver diamine fluoride
Number of subjects: 550

Group type: COMPARATOR
Intervention: Atraumatic restorative treatment + biannual fluoride varnish
Number of subjects: 550
Study: 32897402

Group type: EXPERIMENTAL
Intervention: NLG207 (nanoparticle-bound camptothecin)
Number of subjects: 27
Study: 32897466

Group type: EXPERIMENTAL
Intervention: CE 3D T1-weighted fast field echo (3D T1-WI)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CE 2D spin echo T1-weighted image (2D T1-WI)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CE 2D T2 FLAIR
Number of subjects: 35

Group type: COMPARATOR
Intervention: CE 2D T2 FLAIR added to CE 3D T1-WI
Number of subjects: 35
Study: 32897830

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg daily
Number of subjects: 23
Study: 32898224

Group type: EXPERIMENTAL
Intervention: Nomogram-Based Preoperative Score (NBPS)
Number of subjects: 150
Study: 32898244

Group type: EXPERIMENTAL
Intervention: AMG 701
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AMG 701 + lenalidomide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AMG 701 + pomalidomide
Number of subjects: 0

Group type: COMPARATOR
Intervention: IMiDs (lenalidomide and pomalidomide)
Number of subjects: 0
Study: 32898291

Group type: EXPERIMENTAL
Intervention: PGT-A with polar body biopsy
Number of subjects: 2794

Group type: EXPERIMENTAL
Intervention: PGT-A with blastocyst stage biopsy
Number of subjects: 2794

Group type: EXPERIMENTAL
Intervention: PGT-A with FISH
Number of subjects: 2794

Group type: COMPARATOR
Intervention: IVF without PGT-A
Number of subjects: 2794
Study: 32898333

Group type: EXPERIMENTAL
Intervention: Pyrotinib plus SHR6390
Number of subjects: 5
Study: 32898919

Group type: EXPERIMENTAL
Intervention: Computerized image analysis of blood vessels in the mucosal defect
Number of subjects: 86
Study: 32899054

Group type: EXPERIMENTAL
Intervention: Tuberculin skin test (TST) performed before traveling and again 8-12 weeks after return, along with QuantiFERON-TB Gold Plus test.
Number of subjects: 492
Study: 32900326

Group type: EXPERIMENTAL
Intervention: Advanced critical care interventions
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Older age and pre-admission hypertension
Number of subjects: 73
Study: 32900657

Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 44
Study: 32900761

Group type: EXPERIMENTAL
Intervention: Changes in medication purchases (painkillers and indigestion medication) 10-12 months before ovarian cancer diagnosis
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Pre-existing loyalty card data
Number of subjects: 1000
Study: 32901324

Group type: EXPERIMENTAL
Intervention: Serum lipase > 51 U/L on POD3
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: IL-6 > 56.5 ng/l on POD3
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Combination of serum lipase and IL-6 on POD3
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Patients with both or one factor(s) above cut-off
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Overall and severe complications
Number of subjects: 70
Study: 32902099

Group type: EXPERIMENTAL
Intervention: Oral Anticoagulation Therapy (OAT)
Number of subjects: 390
Study: 32902182

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell transplantation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Educational intervention based on the Early Start Denver Model
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell transplantation combined with educational intervention
Number of subjects: 30
Study: 32902200

Group type: COMPARATOR
Intervention: Lurasidone
Number of subjects: 1223

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 1223

Group type: COMPARATOR
Intervention: QUE-XR
Number of subjects: 1223
Study: 32902390

Group type: EXPERIMENTAL
Intervention: Internet-mediated, pedometer-based physical activity intervention for 12 weeks
Number of subjects: 59
Study: 32902391

Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate (VLC) diet with text messages
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate (VLC) diet with gifts of food and cookbooks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Very low-carbohydrate (VLC) diet with urine-based ketone self-monitoring
Number of subjects: 44

Group type: COMPARATOR
Intervention: Very low-carbohydrate (VLC) diet without enhancement strategies (control group not explicitly mentioned)
Number of subjects: 44
Study: 32902743

Group type: EXPERIMENTAL
Intervention: Initial Diamond-Forrester (D+F) prediction model
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Updated Diamond-Forrester (D+F) prediction model
Number of subjects: 1440
Study: 32902763

Group type: EXPERIMENTAL
Intervention: Fundal pressure
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control (spontaneous delivery without fundal pressure)
Number of subjects: 86
Study: 32903033

Group type: EXPERIMENTAL
Intervention: STAR-guided AFD ablation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pulmonary vein isolation
Number of subjects: 30
Study: 32903035

Group type: EXPERIMENTAL
Intervention: Radiopharmaceutical administrations during diagnostic nuclear medicine procedures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care scans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detailed analysis of radiation dose calculations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current risk models
Number of subjects: 0
Study: 32903104

Group type: EXPERIMENTAL
Intervention: Office blood pressure measurement
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory blood pressure measurement
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Office blood pressure
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure
Number of subjects: 267
Study: 32903199

Group type: EXPERIMENTAL
Intervention: Convalescent Plasma (CP) infusion
Number of subjects: 575

Group type: COMPARATOR
Intervention: Matched controls (no CP due to lack of consent or availability)
Number of subjects: 575
Study: 32903267

Group type: EXPERIMENTAL
Intervention: Karate intervention (10-week, twice weekly classes)
Number of subjects: 19
Study: 32903355

Group type: EXPERIMENTAL
Intervention: Enhanced treadmill training with real-time visualisation feedback and functional electrical stimulation
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation to pre-tibial muscles
Number of subjects: 6
Study: 32903368

Group type: EXPERIMENTAL
Intervention: Psychological therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 32903394

Group type: EXPERIMENTAL
Intervention: Dance Movement Therapy (DMT) + Treatment as Usual (TAU)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 109
Study: 32903594

Group type: EXPERIMENTAL
Intervention: First-Line Treatment
Number of subjects: 0
Study: 32903623

Group type: EXPERIMENTAL
Intervention: Personalized medicine intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32904162

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg + Ezetimibe 10 mg (R/E)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Simvastatin 20 mg + Ezetimibe 10 mg (S/E)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg + Ezetimibe 10 mg (R/E)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Simvastatin 40 mg + Ezetimibe 10 mg (S/E)
Number of subjects: 129
Study: 32904642

Group type: EXPERIMENTAL
Intervention: Electro-Acupuncture (EA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manual Acupuncture (MA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both EA and MA
Number of subjects: 0
Study: 32905581

Group type: EXPERIMENTAL
Intervention: HIV patients with COVID-19
Number of subjects: 286
Study: 32905623

Group type: EXPERIMENTAL
Intervention: Lower blood pressure targets (135/85 mmHg or less)
Number of subjects: 9484

Group type: COMPARATOR
Intervention: Standard blood pressure targets (140 to 160/90 to 100 mmHg or less)
Number of subjects: 9484
Study: 32905674

Group type: COMPARATOR
Intervention: Recombinant factor VIII at a dose of 25 IU/kg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Recombinant factor VIII at a dose of 65 IU/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: BIVV001 at a dose of 65 IU/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: BIVV001
Number of subjects: 16
Study: 32905725

Group type: EXPERIMENTAL
Intervention: Methadone, gabapentin, propofol, and remifentanil as part of a new clinical pathway
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (historically collected)
Number of subjects: 39
Study: 32905959

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg every 3 weeks until loss of clinical benefit or unacceptable toxicity
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 35
Study: 32906162

Group type: EXPERIMENTAL
Intervention: EN-580XP system
Number of subjects: 295

Group type: COMPARATOR
Intervention: EN-580T system
Number of subjects: 295
Study: 32907357

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 400 mg daily during pregnancy
Number of subjects: 45
Study: 32907594

Group type: EXPERIMENTAL
Intervention: Silent Visuomotor Cues (SVC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Semantic Auditory Cues (SAC)
Number of subjects: 10
Study: 32907626

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 40
Study: 32907766

Group type: EXPERIMENTAL
Intervention: Mindfulness therapy applied to experimental group patients
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Mindfulness therapy (experimental group)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 112
Study: 32907782

Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM) therapy with the InterStim™ system
Number of subjects: 320
Study: 32907899

Group type: EXPERIMENTAL
Intervention: Individual-level factors (e.g., walking distance to health facility, ANC visits, last birth at health facility, number of children, knowledge on FP, intentions to use FP)
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Community-level factors (e.g., electronic media possession, women's decision making on FP)
Number of subjects: 891
Study: 32907924

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenously every 2 weeks
Number of subjects: 156
Study: 32908159

Group type: EXPERIMENTAL
Intervention: EDOF IOL (Tecnis Symfony IOL)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Trifocal IOL (FineVision PodFT, PhysIOL)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Mix-and-Match bifocal IOLs
Number of subjects: 3

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 3
Study: 32908559

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous needle electrolysis (PNE) in combination with an eccentric exercise program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 30
Study: 32908956

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32909218

Group type: EXPERIMENTAL
Intervention: Same-day initiation (SDI) of antiretroviral therapy (ART)
Number of subjects: 593

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 593

Group type: EXPERIMENTAL
Intervention: Same-day initiation (SDI) of ART
Number of subjects: 593
Study: 32909523

Group type: EXPERIMENTAL
Intervention: Behavior Change Technique Taxonomy applied to childhood obesity interventions
Number of subjects: 0
Study: 32909605

Group type: EXPERIMENTAL
Intervention: CMV-seropositivity
Number of subjects: 10122

Group type: COMPARATOR
Intervention: Highest CMV IgG quartile
Number of subjects: 10122
Study: 32909630

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-intrauterine system (LNG-IUS)
Number of subjects: 1657
Study: 32909953

Group type: EXPERIMENTAL
Intervention: 18F-choline PET/CT (FCH-PET)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 18F-fluorodeoxyglucose PET/CT (FDG-PET)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Whole-body MRI (WB-MRI)
Number of subjects: 30
Study: 32909954

Group type: EXPERIMENTAL
Intervention: SmartMoms in WIC intervention (intensive 24-week behavioral intervention including nutrition education and exercise strategies, delivered through a website application)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: SmartMoms in WIC intervention
Number of subjects: 432
Study: 32909970

Group type: EXPERIMENTAL
Intervention: Intrauterine vacuum-induced hemorrhage-control device
Number of subjects: 107
Study: 32910099

Group type: EXPERIMENTAL
Intervention: High-dose spinal cord stimulation (HD-SCS)
Number of subjects: 194
Study: 32910151

Group type: EXPERIMENTAL
Intervention: Doxorubicin plus pembrolizumab (45 and 75 mg/m2)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Doxorubicin plus pembrolizumab
Number of subjects: 37
Study: 32910338

Group type: EXPERIMENTAL
Intervention: pegilodecakin+FOLFOX
Number of subjects: 39
Study: 32910360

Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 91
Study: 32910531

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Tofacitinib (both doses)
Number of subjects: 710

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Tofacitinib
Number of subjects: 710
Study: 32910776

Group type: EXPERIMENTAL
Intervention: rs738409(G) SNP variant
Number of subjects: 917

Group type: EXPERIMENTAL
Intervention: SIRD cluster members
Number of subjects: 917
Study: 32910816

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) assessed via accelerometer
Number of subjects: 7280
Study: 32911050

Group type: EXPERIMENTAL
Intervention: Boston Scientific ImageReady ICD (n = 39) or CRT-D (n = 191)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: MRI Protection Mode turned on
Number of subjects: 230
Study: 32911703

Group type: EXPERIMENTAL
Intervention: Cytochrome P450 intervention, details not specified
Number of subjects: 0
Study: 32912180

Group type: EXPERIMENTAL
Intervention: Melatonin 1, 2, or 4 mg granules orally
Number of subjects: 99
Study: 32912268

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (tenofovir) for prevention of mother to child transmission (PMTCT) of hepatitis B virus (HBV)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (tenofovir)
Number of subjects: 171
Study: 32912364

Group type: EXPERIMENTAL
Intervention: Arterial Hypertension (AH) present
Number of subjects: 319

Group type: COMPARATOR
Intervention: No Arterial Hypertension (AH)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Elevated blood pressure levels on BP Holter 1 month after discharge
Number of subjects: 319
Study: 32912460

Group type: EXPERIMENTAL
Intervention: Transcatheter tricuspid valve intervention (TTVI)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Massive or torrential TR
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Procedural success
Number of subjects: 333
Study: 32912472

Group type: EXPERIMENTAL
Intervention: Thin-cap fibroatheromas (TCFAs)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Fibrous plaques
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Patients with acute coronary syndromes (ACS)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Patients without acute coronary syndromes (ACS)
Number of subjects: 131
Study: 32912664

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (WP) monotherapy
Number of subjects: 188
Study: 32912788

Group type: EXPERIMENTAL
Intervention: Serum uric acid (SUA) levels
Number of subjects: 2569
Study: 32912957

Group type: EXPERIMENTAL
Intervention: Long-term breast cancer survivors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Women without breast cancer (control group)
Number of subjects: 0
Study: 32913286

Group type: EXPERIMENTAL
Intervention: sapanisertib 5 mg QD
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: sapanisertib 40 mg QW
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: sapanisertib 30 mg QW
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: sapanisertib QD, QW, QD × 3dQW, QD × 5dQW
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: sapanisertib
Number of subjects: 31
Study: 32913660

Group type: EXPERIMENTAL
Intervention: Telehealth resilience-building intervention
Number of subjects: 62
Study: 32913914

Group type: EXPERIMENTAL
Intervention: Behavioral interventions targeting lifestyle and cardiovascular disease risk
Number of subjects: 0
Study: 32913985

Group type: EXPERIMENTAL
Intervention: RNA-seq classifiers for hormone responsiveness
Number of subjects: 3678

Group type: EXPERIMENTAL
Intervention: MGC hormone-responsive classifier
Number of subjects: 3678

Group type: COMPARATOR
Intervention: RNA-seq classifiers
Number of subjects: 3678
Study: 32914038

Group type: EXPERIMENTAL
Intervention: Experimental arms of innovative glioblastoma therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard concurrent temozolomide and radiation therapy followed by adjuvant temozolomide (Control)
Number of subjects: 0
Study: 32914172

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intravaginal ring (IVR) delivering 40 µg LNG per day
Number of subjects: 1471

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intravaginal ring (IVR)
Number of subjects: 1471
Study: 32914187

Group type: EXPERIMENTAL
Intervention: BDG concentration >100 pg/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple (≥2) positive results >100 pg/mL or a BDG concentration increasing >100 pg/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BDG concentration >100 pg/mL in patients with IC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BDG concentration ≤100 pg/mL in patients with IC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BDG concentration >100 pg/mL in patients without IC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Micafungin
Number of subjects: 0
Study: 32914581

Group type: EXPERIMENTAL
Intervention: Desmopressin 25-μg ODTs
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Desmopressin 50-μg ODTs
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Desmopressin ODTs (25 and 50 μg)
Number of subjects: 503
Study: 32914672

Group type: EXPERIMENTAL
Intervention: Nonhyperemic pressure ratios (NHPRs) including instantaneous wave-free ratio, resting full-cycle ratio, and diastolic pressure ratio ≤0.89
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Fractional flow reserve (FFR) ≤0.80
Number of subjects: 435

Group type: COMPARATOR
Intervention: Negative NHPRs
Number of subjects: 435

Group type: COMPARATOR
Intervention: Negative FFR
Number of subjects: 435
Study: 32915072

Group type: EXPERIMENTAL
Intervention: Rehabilitation levels in patients with COVID-19
Number of subjects: 0
Study: 32915162

Group type: EXPERIMENTAL
Intervention: Work2Prevent (W2P) employment intervention program
Number of subjects: 41
Study: 32915349

Group type: EXPERIMENTAL
Intervention: Levoamlodipine maleate (n=5018)
Number of subjects: 10031

Group type: COMPARATOR
Intervention: Amlodipine besylate (n=5013)
Number of subjects: 10031

Group type: EXPERIMENTAL
Intervention: Levoamlodipine maleate
Number of subjects: 10031
Study: 32915384

Group type: EXPERIMENTAL
Intervention: Daratumumab subcutaneous (DARA SC) 1,800 mg
Number of subjects: 6
Study: 32915419

Group type: EXPERIMENTAL
Intervention: Crenigacestat (75 mg escalating to 150 mg TIW for 2 weeks, then 50 mg TIW) + Prednisone (co-administered for 2 weeks in Cycle 1)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Crenigacestat (75 mg TIW)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Crenigacestat (100 mg BIW)
Number of subjects: 28
Study: 32915679

Group type: EXPERIMENTAL
Intervention: CaboNivo (cabozantinib 40 mg/d plus nivolumab 3 mg/kg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CaboNivoIpi (cabozantinib 40 mg/d, nivolumab 3 mg/kg, and ipilimumab 1 mg/kg)
Number of subjects: 54
Study: 32915950

Group type: EXPERIMENTAL
Intervention: AAV5 gene therapy producing B-domain-deleted FVIII (FVIII-SQ)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Transgene-produced FVIII-SQ
Number of subjects: 2

Group type: COMPARATOR
Intervention: CS activity
Number of subjects: 2
Study: 32915978

Group type: EXPERIMENTAL
Intervention: Momelotinib (MMB)
Number of subjects: 41
Study: 32916296

Group type: EXPERIMENTAL
Intervention: Tiotropium + Olodaterol fixed-dose combination (5 μg/5 μg)
Number of subjects: 12